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INTRODUCTION
Targeted drug delivery using nanocontainers is one
of the actively developing areas of nanotechnology [1,
2]. Compounds with the structure of keplerates (buck
yballs or fullerenes) and unified under the name poly
oxometalates (POMs), which were first synthesized by
Professor A. Müller (University of Bielefeld, Ger
many) [3, 4], are promising for use as nanocontainers.
POMs possess the following advantageous character
istics: solubility in water and the ability to absorb
reversibly various organic compounds [5], form com
plexes [6], and move under the influence of weak elec
tric fields [5].
An iron–molybdenum buckyball Mo72Fe30 is one
of the most typical representatives of the class of buck
yballs [4].
[Mo72Fe30O252(CH3COO)12{Mo2O7(H2O)}2{H2Mo2O8(H2O)}(H2O)91] ≈ 150H2O.
The presence of an internal cavity and “windows”
through which the exchange of water and different
substances can occur in the structure of this keplerate
makes its application as a nanocontainer possible.
Unlike other prospective nanocontainers (carbon
fullerenes) [7], POMs are able to decompose, forming
simpler compounds of molybdenum and iron [5, 6],
which further participate in the metabolic processes
natural for the organism.
In particular, molybdenum takes part in the oxida
tion–reduction reactions as a cofactor of oxidases.
Despite the absence of cumulation of soluble molyb
denum compounds, its chronic excessive intake can be
accompanied by the deposition of uric acid and urates
[8, 9], which cause the symptoms of arthragra [8, 9].
The accelerated formation of uric acid is due to the
activation of hypoxanthine oxidase and xanthine oxi
dase molybdenumdependant enzymes, which cata
lyze the oxidation of purine bases [8]. The excessive
intake of iron, in contrast to that of molybdenum,
damages various organs owing to the deposition of
hemosiderin. Because of the participation of iron in
the Fenton reaction, free radical oxidation is triggered.
Because the effects of nanosized materials can dif
fer from the effects of the element constituting these
particles, a thorough investigation into the toxicity of
buckyballs is required.
Thus, the aim of this work is to investigate the acute
and subacute toxicity of iron–molybdenum bucky
balls intended for use as containers for targeted drug
delivery.
MATERIALS AND METHODS
The synthesis of Mo72Fe30 was carried out according to
the literature procedure [4]. The preparation of Mo72Fe30
nanocluster was carried out in two steps, and nanocluster
(NH4)42[ O372(CH3COO)30(H2O)72] ·
300H2O · 10CH3COONH4(Mo132) was an intermedi
ate product [3]. Starting reagents in the synthesis of
Mo132 were chemically pure grade ammonium hepta
molybdate (NH4)6Mo7O24 · 4H2O, pureforanalysis
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grade hydrazine sulfate N2H4 · H2SO4, chemically
pure grade ammonium acetate CH3COONH4, chem
ically pure grade glacial acetic acid CH3COOH, and
medicalgrade ethanol 95%. For the synthesis of
Mo72Fe30 from Mo132, iron chloride (III) hexahydrate
FeCl3 · 6H2O Panreac (assay 97–102%), purefor
analysisgrade sodium acetate Na(CH3COO) · 3H2O,
high purity grade hydrochloric acid HCl, and pure
foranalysisgrade sodium chloride NaCl were used.
The synthetic methodologies involve the washing of
the intermediate compound and final product, upon
which the admixtures of starting materials, which are
more soluble in the washing conditions compared to
the nanocluster polyoxometalates themselves, were
removed. In order to control the quality of washing,
particularly from the residual iron chloride, the wash
ing liquid was analyzed for the absence of the chloride
ions. The synthesized compounds Mo132 and Mo72Fe30
were characterized, and their characteristics were
compared with the literature data by an elemental
analysis method using an autoanalyzer Carlo Erba
CHNSOEA1108 for a C, N, H and atomic emission
spectrometer with inductively coupled plasma iCAP
6500 Duo (Thermo Scientific) for molybdenum and
iron; by a dynamic laser light scattering method using
a universal suspension analyzer Brookhaven Zeta
Plus/B1 90 with a wavelength of 659 nm in relation to
the size of the nanoclusters; by structural characteris
tics using a SpectrumBX II Fourier IR spectrometer
(PerkinElmer) in KBr pellets, a spectrophotometer
Heliosα, and a Raman spectrometer Triplimate 21.
The intermediate compound Mo132 was analyzed for
the absence of toxic admixtures like hydrazine by
NMR spectroscopy using a Bruker DRX400 NMR
spectrometer; 2,2dimethyl2silapentane5sulfonate
(DSS) was used as an internal standard and the samples
were dissolved in D2O. The intermediate and final com
pound Mo72Fe30 was also analyzed in the powdered
condition for the absence of admixtures, including
residual salts of molybdenum and iron, by Xray anal
ysis using a diffractometer D8 ADVANCE, Bruker
(CuK
α
 emission).
The experiment for the investigation into acute and
subacute toxicity was carried out on 95 outbred rats of
both sexes and with body weights of 200–230 g, which
were on a standard feed of the vivary. Housing condi
tions and treatment of animals used in the experiment
corresponded the EU Council Directive of November
24, 1986, “On the Approximation of Laws, Regula
tions and Administrative Statutes of the EU on the
Protection of Animals Used for Experimental and
Other Scientific Purposes” (86/609EEC). The ani
mals were divided into 12 groups. The first group con
sisted of intact rats (ten animals). In investigational
groups 2–7 (ten rats each), the introduction of various
dosages of nanoparticles was performed in three dif
ferent ways. Groups 2c–7c (five animals each) were
the control groups in relation to the investigational
ones; the animals in these groups were administered
distilled water in the same volumes and in the same
ways as the rats in the investigational groups were
administered buckyballs. The buckyballs were injected
into the animals in groups 2 and 3 intramuscularly as a
single dose of 0.15 mg/100 g. The animals were with
drawn from the experiment 1 and 24 h after injection,
correspondingly. In group 4, the test material was intro
duced intraperitoneally, the dose was 0.15 mg/100 g,
and the withdrawal from the experiment was per
formed after 24 h. In groups 5 and 6, the buckyballs
were introduced intragastrically and the doses were
0.50 mg/100 g and 30 mg/100 g, correspondingly; the
action of the nanoparticles continued for 24 h.
In group 7, the animals were injected iron–molybde
num buckyballs intramuscularly for 30 days on a daily
basis in the dosage of 0.15 mg/100 g.
It was established earlier that the area of acceptable
over time stability for buckyballs is a weak acidic or
neutral medium, and the best method for buckyball
introduction, namely intramuscular injections, was
chosen [10, 11]. The amount of molybdenum con
tained in one injection of buckyballs corresponded to
the upper limit of normal for the daily intake of molyb
denum, and the amount of iron was 21.5fold less than
its daily intake. The animals were withdrawn from the
experiment by ether anesthesia. The content of
molybdenum in the organs was determined using an
atomic emission spectrometer with inductively cou
pled plasma iCAP6500 Duo (Thermo Scientific)
after the mineralization of samples.
Biochemical studies characterizing the cytolytic
activity of the injected substances and their influence
on the functional state of various organs were per
formed according to the “Guideline for the Experi
mental (Preclinical) Investigation of New Pharma
ceutical Substances of the Ministry of Public Health of
the Russian Federation” [12]. In the blood plasma, the
activity of the following enzymes was determined: aspar
tate aminotransferase or AST (EC 2.6.1.1), alanine ami
notransferase or ALT (EC 2.6.1.2), alkaline phosphatase
(EC 3.1.3.1.), and αamylase (EC 3.2.1.1.), as well as
the content of glucose, creatinine and total protein. Vital
diagnostics (St. Petersburg) readytouse reagents kits
were used for the investigation. The optical density was
measured using an SF56 spectrophotometer.
The statistical analysis of the material was carried out
using Statistica 6.0 (StatSoft, Inc.) and Microsoft Excel
2003 programs. A significance level of 5% (P < 0.05) was
used upon the examination of statistical hypotheses.
RESULTS AND DISCUSSION
The qualification of the synthesized nanocluster
Mo72Fe30 by a set of physicochemical methods
revealed that its chemical composition and structure
were in a good agreement with the literature data [4]
and that it was of high purity.
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In order to determine acute toxicity, a solution and
a suspension of the iron–molybdenum buckyballs
with the highest possible concentration were prepared
and three ways for the injection of the buckyballs were
chosen: intramuscular (I.M.), intraperitoneal (I.P.),
and intragastric (I.G.). The concentration of the solu
tion of the iron–molybdenum buckyballs for intra
muscular and intraperitoneal injection was 1 g/L and
corresponded to the maximum solubility of these
nanoparticles. Taking into account the fact that the
maximum liquid volume for parenteral infusion is
0.3 mL, the maximum dosage for groups of animals
1 and 2 was 0.15 mg/100 g. For rats, the admissible liq
uid volume for intragastric infusion is 1 mL; in this
case, the buckyball load was 0.50 mg/100 g. In contrast
to the parenteral administration, peroral administra
tion allows introducing the suspension of buckyballs
with the concentration of 60 mg/mL, which corre
sponds to a maximum dosage of 30 mg/100 g.
The administration of the maximum possible dose
of buckyballs was not accompanied by any lethality;
therefore, one can conclude that the investigational
material is not highly toxic, because the amount of the
nanoparticles (30 mg/100 g) was 200fold higher than
a proposed therapeutic dosage (0.15 mg/100 g).
The biochemical characteristics of the functional
state of various organs were determined in the blood
plasma of animals from all groups according to the
guideline for the experimental (preclinical) investiga
tion of new pharmaceutical substances [12].
The data on the biochemical measurements in rats
from experimental groups after the administration of
various doses of iron–molybdenum buckyballs in
comparison with the same data for the control groups,
in which animals were administered an equivalent
amount of distilled water in three different ways, are
presented in Tables 1 and 2.
As is seen from Table 1, there are no deviations in
the investigated parameters from the control (group 2c)
Table 1. Biochemical parameters of the animal blood plasma on several days after the intramuscular injection of iron–
molybdenum buckyballs (dosage 0.15 mg/100 g)
Parameter
2
I.M. single 
dose 1 h
2c
Control for 
group 2
3
I.M. single 
dose 24 h 
3c
Control for 
group 3
7
I.M. multiple 
doses 30 days
7c
Control for 
group 7
Glucose, mmol/L 5.9 ± 0.8 7.3 ± 0.3 8.0 ± 0.8 6.5 ± 0.4 7.4 ± 0.6 7.1 ± 0.2
AST, U/l 15.3 ± 0.6 13.6 ± 0.5 26.3 ± 1.5* 12.9 ± 0.5 15.4 ± 1.6 13.7 ± 0.6
ALT, U/l 10.4 ± 0.4 10.9 ± 0.8 9.6 ± 1.1 8.9 ± 0.4 10.0 ± 0.8 9.6 ± 0.5
AST/ALT 1.47 ± 0.06 1.28 ± 0.11 2.93 ± 0.47* 1.47 ± 0.10 1.55 ± 0.06 1.44 ± 0.10
Alkaline phos
phatase, U/l
53.6 ± 4.2 48.9 ± 2.8 36.8 ± 4.7* 51.0 ± 2.5 44.3 ± 6.2 48.2 ± 3.5
αAmylase, mg/(s L) 31.5 ± 2.2 33.1 ± 1.8 29.7 ± 1.7 33.9 ± 1.4 33.6 ± 4.6 29.7 ± 1.3
Total protein, g/L 65.7 ± 1.9 73.9 ± 2.0 68.2 ± 1.7 72.2 ± 2.7 68.6 ± 2.7 74.3 ± 2.4
Creatinine μmol/L 57.4 ± 1.2 66.4 ± 5.3 59.0 ± 2.9 62.3 ± 4.9 83.7 ± 5.6 69.4 ± 3.4
* Differences with the corresponding control group are statistically significant at P < 0.05.
Table 2. Biochemical parameters of the animal blood plasma 24 h after a single dosage of iron–molybdenum buckyballs in
a number of ways
Parameter 4I.P. 0.15 mg/100 g
4c
Control for group 4
5
I.G. 0.50 mg/100 g
6
I.G. 30 mg/100 g
5c
Control for 
groups 5 and 6
Glucose,  mmol/L 9.1 ± 0.5 8.7 ± 0.6 7.8 ± 1.4 10.1 ± 1.0* 7.0 ± 0.3
AST, U/l 19.6 ± 1.1* 14.2 ± 0.5 21.6 ± 2.4* 24.1 ± 2.2* 14.0 ± 0.4
ALT, U/l 13.1 ± 1.6 9.9 ± 0.5 16.7 ± 3.1* 18.0 ± 2.6* 9.2 ± 0.6
AST/ALT 1.54 ± 0.10 1.44 ± 0.04 1.35 ± 0.21 1.36 ± 0.09 1.55 ± 0.09
Alkaline phosphatase, U/l 39.1 ± 2.8* 49.8 ± 3.0 48.5 ± 6.1 38.5 ± 2.6* 51.1 ± 4.0
αAmylase, mg/(s L) 32.0 ± 2.0 32.9 ± 0.7 28.4 ± 2.8 31.3 ± 4.0 30.3 ± 3.7
Total protein, g/L 65.0 ± 3.8 71.2 ± 2.2 69.4 ± 10.3 65.9 ± 3.0 72.8 ± 2.2
Creatinine, μmol/L 63.6 ± 2.3 68.8 ± 5.0 58.8 ± 2.7 66.9 ± 3.5 68.6 ± 5.4
* Differences with the corresponding control group are statistically significant at P < 0.05.
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1 h after the injection of nanoparticles (group 2). At
the same time, 24 h after the intragastric infusion of
buckyballs (group 6) there is a statistically reliable
increase in the glucose content compared to the corre
sponding control group (Table 2). The increase in the
glucose level, which is a nonspecific symptom of dys
crasia, can be due to both the very procedure for the
introduction of intragastric probe and the toxic action
of the increased amount of buckyballs (30 mg/100 g).
It was also observed that the activity of AST
increased 24 h after the infusion of buckyballs by each
of the three methods used (groups 3–6) and the activ
ity of ALT increased after the intragastric infusion of
nanoparticles (groups 5–6) relative to these same
parameters in the control animals which were admin
istered distilled water (Tables 1, 2).
In group 3, the activity ratio for the enzymes
AST/ALT was also above the norm. The reproportion
of the activities of aminotransferases in favor of AST
points to the predominant increase in the permeability
of the membranes of cardiomyocytes. The increase in
the AST activity and de Ritis coefficient under the
shortterm action of the nanomaterial did not depend
on the amount of the specimen introduced and was
more pronounced in the case of intramuscular
injection.
In ordered to elucidate the influence of the proce
dure for the injection of the buckyballs, the biochemi
cal parameters of intact animals and rats from the con
trol groups were compared (Table 3). A small statisti
cally significant (P < 0.05) increase of the glucose
content was only observed after the intraperitoneal
injection of water compared to the same data for the
intact animals (group 4c). In the rest of the control
groups to the investigational groups 2, 3, 5, 6, and 7, the
examined parameters did not differ statistically signifi
cantly from the level of the parameters for intact ani
mals. Hence, dyscrasia, whose symptoms are abnormal
glucose content and enzyme strength, was due to the
action of the nanoparticles.
In groups 5 and 6, ALT activity increased 24 h after
the intragastric injection of buckyballs (Table 2). It is
likely that the activity of ALT, which is an indicator of
liver damage, was influenced by the injection method
(intragastric) under which the buckyballs can get to
the liver faster compared to other injection methods.
At the same time, the AST : ALT ratio in groups 5 and
6 did not statistically significantly differ from this coef
ficient for intact animals, which does not allow estab
lishing the accurate localization of cytolysis.
The histological study of liver conducted earlier did
not indicate any structural changes in hepatocytes
after the 30day action of buckyballs [11]; at the same
time, the hyperemia of central veins and the veins of
portal tracts provided evidence for the onset of the
symptoms of an inflammatory process. In part of the
liver blood vessels of rats from group 7, “sludge com
plexes” were detected, the formation of which is
apparently due to the increase in the amount of
thrombocytes, erythrocytes, and hematocrit values
because of the repetitive intake of iron [12]. The total
amount of leucocytes and nuclear Arneth count of the
rats injected with buckyballs for 30 days did not differ
statistically significantly from the parameters of the
peripheral blood of intact rats, which gives evidence of
the absence of an inflammatory process of the whole
organism.
The absence of an increase in the activity of alka
line phosphatase, which is one of the indicators of
cholestasis, in the blood plasma of all experimental
rats points to the integrity of the cholepoietic function
of hepatocytes after the shortterm and longterm
injection of buckyballs (Tables 1, 2).
Alkaline phosphatase is also a specific enzyme of
osteoblasts and participates in mineralization, and the
activity of this enzyme is an indicator of the speed
change in the remodeling of mineral components in
the bone tissue. It is a known fact that molybdates can
reduce the activity of phosphatases, apparently, due to
the interaction of molybdates with the thiol groups of
Table 3. Biochemical parameters of the animal blood plasma after the injection of water in a number of ways
Parameter 1Intact
2c
0.3 mL H2O
I.M. after 1 h
3c
0.3 mL H2O
I.M. after 24 h
4c
0.3 mL H2O
I.P. after 24 h 
5c
0.3 mL H2O
I.G. after 24 h
7c
0.3 mL H2O
I.M. 30 days
Glucose, mmol/L 6.9 ± 0.1 7.3 ± 0.3 6.5 ± 0.4 8.7 ± 0.6* 7.0 ± 0.3 7.1 ± 0.2
AST, U/l 13.2 ± 0.7 13.6 ± 0.5 12.9 ± 0.5 14.2 ± 0.5 14.0 ± 0.4 13.7 ± 0.6
ALT, U/l 9.1 ± 0.5 10.9 ± 0.8 8.9 ± 0.4 9.9 ± 0.5 9.2 ± 0.6 9.6 ± 0.5
AST/ALT 1.46 ± 0.10 1.28 ± 0.11 1.47 ± 0.10 1.44 ± 0.04 1.55 ± 0.09 1.44 ± 0.10
Alkaline phos
phatase, U/l
50.4 ± 3.0 48.9 ± 2.8 51.0 ± 2.5 49.8 ± 3.0 51.1 ± 4.0 48.2 ± 3.5
αAmylase, mg/(s L) 29.7 ± 2.9 33.1 ± 1.8 33.9 ± 1.4 32.9 ± 0.7 30.3 ± 3.7 29.7 ± 1.3
Total protein, g/L 72.0 ± 2.7 73.9 ± 2.0 72.2 ± 2.7 71.2 ± 2.2 72.8 ± 2.2 74.3 ± 2.4
Creatinine, μmol/L 65.8 ± 6.2 66.4 ± 5.3 62.3 ± 4.9 68.8 ± 5.0 68.6 ± 5.4 69.4 ± 3.4
* Differences with the group of intact animals are statistically significant at P < 0.05.
676
NANOTECHNOLOGIES IN RUSSIA  Vol. 8  Nos. 9–10  2013
OSTROUSHKO et al.
cysteine and imidazole groups of histidine located in
the active sites of these enzymes [9].
In groups 3, 4, and 6, a negligible but statistically
significant decrease in the activity of alkaline phos
phatase was detected, which is probably due to the
inhibiting action of molybdenum. A shortterm—over
24 h—decrease in the activity of alkaline phosphatase
eliminates the risk of the development of osteoporosis
upon a single injection of buckyballs.
In a comparison of the mean values for other
parameters in groups 2–6 (the activity of αamylase
and content of total protein and creatinine in the
blood plasma), no statistically significant differences
with the parameters of the intact and control rats were
detected, which gives evidence of the absence of the
pronounced changes in kidneys, liver, and pancreas of
the animals from these groups. In group 7 (with the
subacute injection of buckyballs), no statistically sig
nificant deviations from the norm for all tested bio
chemical parameters were detected either, which
makes it possible to suppose the absence of the pro
cesses of cytolysis and the damage of kidneys, liver,
myocardium, pancreas, and bone tissue after a daily
injection of buckyballs.
An investigation into the molybdenum content in
the blood of the animals after the injection of nanopar
ticles by different ways is presented in Table 4.
A statistically significant increase in the molybde
num content in blood after a onetime load with buck
yballs, regardless of the method used for their injec
tion, was noted. The amount of molybdenum detected
in blood 24 h after the injection of buckyballs
increased proportionately with the amount of the
nanomaterial injected (groups 3, 4, and 5). A signifi
cant decrease in the molybdenum level in blood after
24 h (group 3) compared to the content of this micro
element after 1 h (group 2) following the intramuscu
lar injection and the normalization of this parameter
after daily injections of nanoparticles over a period of
30 days (group 7) are in accordance with the literature
data on the absence of accumulation of molybdenum
[8, 9]. Earlier works also mark the absence of accumu
lation of molybdenum in liver, kidneys, skin, and bone
tissue [10, 11]. Presumably, the decomposition of the
nanoparticles and the accelerated excretion of the ele
ments constituting the buckyballs promote the nor
malization of the parameters under examination (glu
cose, aminotransferase, and alkaline phosphatase),
whose change was detected upon a single dosing of
buckyballs.
CONCLUSIONS
1. The injection of the maximum possible dose of
iron–molybdenum buckyballs (300 mg/kg) was not
accompanied by the lethality of animals.
2. During the investigation into the acute toxicity
of iron–molybdenum buckyballs, no pronounced
changes in the examined parameters of the functional
state of liver, kidneys, and pancreas was detected.
3. During the investigation into the subacute toxic
ity of iron–molybdenum buckyballs, the absence of
accumulation of nanoparticles was established and no
deviations from the norm for the examined parameters
of the functional state of liver, kidneys, pancreas, myo
cardium, or bone tissue were found.
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